Skip to main content

Table 1 Patient characteristics (n = 78)

From: MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Age (years) Mean 56
  Range 24–81
Gender Male 42 (53.8%)
  Female 36 (46.1%)
Tumor location Frontal 20 (25.6%)
  Parietal 13 (16.6%)
  Temporal 13 (16.6%)
  Occipital 11 (14.1%)
  More than one lobe 21 (26.9%)
Duration of symptoms prior to diagnosis < 3 months 60 (76.9%)
  ≥ 3 months 18 (23.1%)
Karnofsky performance score ≥ 60 78 (100%)